Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Change in Cash: 2022-2025

Historic Change in Cash for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Sep 2025 value amounting to -$11.8 million.

  • Corvus Pharmaceuticals' Change in Cash fell 16.37% to -$11.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.8 million, marking a year-over-year increase of 88.25%. This contributed to the annual value of -$3.9 million for FY2024, which is 619.85% down from last year.
  • According to the latest figures from Q3 2025, Corvus Pharmaceuticals' Change in Cash is -$11.8 million, which was down 222.00% from $9.7 million recorded in Q2 2025.
  • Over the past 5 years, Corvus Pharmaceuticals' Change in Cash peaked at $12.4 million during Q3 2023, and registered a low of -$32.0 million during Q1 2022.
  • In the last 3 years, Corvus Pharmaceuticals' Change in Cash had a median value of -$3.5 million in 2023 and averaged -$935,636.
  • The largest annual percentage gain for Corvus Pharmaceuticals' Change in Cash in the last 5 years was 469.99% (2024), contrasted with its biggest fall of 181.63% (2024).
  • Quarterly analysis of 4 years shows Corvus Pharmaceuticals' Change in Cash stood at -$11.4 million in 2022, then surged by 34.51% to -$7.5 million in 2023, then spiked by 154.24% to $4.1 million in 2024, then decreased by 16.37% to -$11.8 million in 2025.
  • Its Change in Cash stands at -$11.8 million for Q3 2025, versus $9.7 million for Q2 2025 and -$3.7 million for Q1 2025.